Tonight's press release. I wonder if the first presentation will be as of a reading date later than 9/30/22. Even if it doesn't, a 2-hour presentation will present a helluva lot more detail than 44% better. The second one is new to me, but it is 4157 specific so it is connected to this trial:
AMBRIDGE, MA / ACCESSWIRE / March 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157/V940 an investigational mRNA personalized cancer vaccine, have been accepted for presentation at the 2023 American Association of Cancer Research (AACR) Annual Meeting being held April 14-19 in Orlando, FL. mRNA-4157/V940 is being jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.
The two abstract titles are:
Presentation #CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open- label Phase 2 mRNA-4157-P201/Keynote-942 trial. Harnessing the Immune System in the Clinic.
Session: Clinical Trials Plenary; Sunday, April 16 at 1:00-3:00 PM ET.
Presenter: Dr. Jeffrey S. Weber
Poster Session #CT224: Evaluation of minimal residual disease as a predictive biomarker of recurrence free survival in high-risk melanoma patients treated with a combination of mRNA-4157, a personalized cancer vaccine, and pembrolizumab.
Session: Phase II Clinical Trials 2; Tuesday, April 18 at 9:00 AM - 12:30 PM ET.
Author: Dr. Ryan J. Sullivan
AACR will post the text of late-breaking and clinical trials abstracts in the AACR Annual Meeting online itinerary planner and Annual Meeting app on April 14, 2023 at 12:00 PM ET.
Moderna's exhibit booth at the AACR Annual Meeting is booth #2664.